PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Mometasone furoate with olopatadine - Allergic rhinitis
PAD Profile : Mometasone furoate with olopatadine - Allergic rhinitis
Keywords :
Hay fever, hayfever, antihistamines, nasal sprays, allergy, seasonal allergic rhinitis, pollen allergy, intranasal corticosteroids, INCS
Brand Names Include :
Ryaltris
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Fluticasone furoate
- Fluticasone with azelastine
- Cetirizine hydrochloride
- Loratadine
- Triamcinolone acetonide
- Beclometasone dipropionate
- Azelastine hydrochloride
- Desloratadine
- Levocetirizine
- Budesonide
- Mometasone furoate
- Ipratropium bromide
- Bilastine
- Mizolastine
- Acrivastine
- Fexofenadine hydrochloride
- Rupatadine fumarate
- House dust mites allergen extract
- White Birch pollen allergen extract
- Chlorphenamine maleate
- Ketotifen fumarate
- Promethazine hydrochloride
- Fluticasone propionate (Nasal)
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 February 2025
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
To be used 2nd line when monotherapy is inadequate.
Associated BNF Codes
12. Ear, Nose and Oropharynx
12.02.01. Drugs used in nasal allergy